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B
y the end of their reproductive life cycle, roughly 40% of women have experienced migraine. Migraine is 3 times more common in women than in men, and worldwide, roughly one-fourth of reproductive-aged women have migraine. Of those who seek headache treatment from their health care professional (HCP), more than 90% meet diagnostic criteria for migraine, 1 yet the majority do not receive a correct diagnosis. In one review, 46% of persons with migraine in the United States thought they had a sinus headache, and 32% thought they had a tension headache. 2 When patients with chronic migraine consult an HCP who is not a headache specialist, only 16% receive a correct diagnosis. 3 The International Classification of Headache Disorders criteria for diagnosis of migraine are summarized in Table 1 . 4 The prevalence of migraine steadily increases through childhood, and the male to female ratio shifts with puberty, when migraine becomes markedly more prevalent in females and remains so throughout the rest of their lives. Most headache centers report that roughly 85% of their patients with migraine are women, and up to 70% of female migraineurs report a menstrual association with their attacks and changes in headaches related to hormonal contraception, pregnancy, and menopause. Thus, patients with menstrual-related migraine (MRM) account for about half of all migraineurs.
Which HCP a woman selects can greatly influence her course of treatment. Traditionally, neurologists are not trained in the hormonal management of MRM or catamenial epilepsy, and most training in gynecology, family medicine, and internal medicine does not delve into the hormonal management of neurologic disorders. A serious need exists to educate HCPs about sex-based differences in migraine and strategies for management of hormonally related headaches.
MENSTRUAL-RELATED MIGRAINE
Menstruation is a potent migraine trigger. By the end of their reproductive years, 40.9% of women have had migraine, 5 and menstrual attacks are up to 4 times more likely to be severe, to be associated with nausea and vomiting, 6 or to be resistant to abortive treatments. 7 Although a review of conventional strategies for management of migraine is beyond the scope of this concise review, prophylactic strategies often include antihypertensives, anticonvulsants, and antidepressants. 8 Hormonal prophylaxis may be helpful for hormonally triggered migraines that do not respond to these treatments and can be used in conjunction with them. Targeted strategies can often be used in which a hormonal agent is prescribed for only a few days in each cycle. A prospective, randomized clinical trial confirmed the efficacy of 1.5 mg of transdermal estradiol gel applied for 7 days, beginning 10 days after ovulation and continued through the second day of menstrual bleeding. 9 In a similar study, 1.5 mg of estradiol gel was effective, whereas lower doses were ineffective. 10 This therapy provides serum estradiol levels of approximately 75 pg/mL (to convert to pmol/L, multiply by 3.671), but efficacy requires correct timing of the intervention.
Some women have noncontraceptive indications that support the use of combined hormonal contraception (CHC), including irregular menstrual cycles, dysmenorrhea, heavy menstrual bleeding, acne, hirsutism, and endometriosis, all of which are commonly managed with CHC. This therapy can be judiciously tailored to prevent the sudden declines in estrogen that trigger MRM.
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One approach is the use of extended-cycle CHC (for 12 weeks). 12 Oral CHC at doses of 20 to 35 mg of ethinyl estradiol (EE) can be used with continuous dosing of the active pills, eliminating the placebo week for months or years. 11, 13 Although some CHC formulations are marketed for extended or continuous use, it is possible to use all monophasic CHC formulations (oral or parenteral) in this manner. Sulak et al 13 reported that MRM was reduced when CHC containing 30 mg of EE was taken in an extended fashion (as opposed to a regimen of 21 days of active drug and 7 days of placebo). If withdrawal bleeding is scheduled, adequate estrogen supplementation (estrogen add-back therapy) can be given with estradiol-17b during the pill-free week to limit the decrease in EE to an equivalent of 10 mg of EE or less; this level has been found to prevent MRM (Table 2) . 12 A CHC vaginal ring that contains 15 mg of EE can also be used with extended-cycle dosing by replacing the ring every 3 to 4 weeks continuously while maintaining contraceptive efficacy.
14 If a withdrawal week is scheduled, a 0.075-mg transdermal estradiol-17b patch can be used during the scheduled week without the CHC ring to limit the decrease in estradiol and prevent MRM. 15 In women who have migraine with aura, the use of CHC is contraindicated according to the Centers for Disease Control and Prevention US medical eligibility criteria for contraceptive use. 16 This concern first arose in the era of high-dose and ultrahigh-dose CHC (50-150 mg of different estrogens). Those extremely high estrogen doses far exceed today's commonly used 20-to 30-mg EE products, and one product has only 10 mg of EE. The controversy is maintained by international studies, including one study that found a small but significantly increased risk of stroke associated with CHC. 17 However, in that study, the women tended to be older (mean age, >35 years) and smokers, and most of the women with stroke had been treated with 50-mg EE CHC. 17 In contrast, large US studies have found that CHC does not increase stroke risk 18 because the doses are lower and CHC is contraindicated in smokers, especially those older than 35 years. Chan et al 19 concluded that the risk of stroke among women taking low-dose oral CHC was "tenuous at best and perhaps nonexistent."
Higher estrogen levels increase the prevalence of aura, 11 and a higher prevalence of aura is associated with higher stroke risk. 17 To reduce peak estrogen levels throughout the menstrual cycle, extended-cycle dosing of an ultralow-dose contraceptive ring (15 mg of EE) can be used in women who have migraine with aura and MRM.
11 A retrospective study of 28 patients found that this treatment strategy decreased aura frequency from 3.2 to 0.2 times a month, and MRM was prevented in 91.3% of users. If a woman does not want to use a ring, the dose of estrogen pills is best limited to the 10-mg EE pill pack, with careful assurance that it is inhibiting ovulation.
In younger adolescent girls, CHC should be used judiciously for preventing MRM because linear growth usually stops about 2 years after menarche, an event thought to be related to the hormones of puberty. When feasible, CHC should not be used until the patient has reached full height; however, this approach increases the risk of undertreatment, which may lead to school absences and chronic migraine. 20 Gonadotropin-releasing hormone antagonists can eliminate pure MRM, but they may also cause adverse effects of estrogen deficiency, limiting the duration of their use. These adverse effects include sleep disruption, a marked reduction in bone density, and severe vasomotor symptoms. They should not be used for more than 6 months without appropriate follow-up. 21 Progestin-only contraceptive pills and intrauterine devices are unlikely to help with MRM because they do not reliably control ovulation. 16 Use of standard-cycle (21 days of hormone and 7 days of placebo) oral CHC is also ineffective, with 2 exceptions: (1) ultralow-dose 10-mg EE CHC (24 days of 10 mg EE with 1 mg norethindrone followed by 2 days of 10 mg EE alone and 2 days of placebo) and (2) quadriphasic estradiol valerate CHC. All other regimens provide at least a 20-mg EE decrease (equivalent to the cyclic decline in natural estrogen) and can therefore trigger MRM in susceptible individuals. 15 
MIGRAINE IN PREGNANCY
During pregnancy, migraine often improves as estradiol levels steadily increase from the first trimester to the third, particularly in women with a history of MRM and migraine without aura. 22 After pregnancy, women who experienced improvement with pregnancy often have a particularly intense migraine shortly after delivery because of the precipitous decrease in estradiol levels. 23 However, some women do not report improvement in migraine with pregnancy, and those in whom migraine continues in the first trimester are likely to continue to have migraine throughout pregnancy and the postpartum period. 23 A minority of women report worsening of migraine in pregnancy, and some experience de novo migraine during pregnancy, most commonly in the first trimester and associated with aura, most likely related to the much higher (and increasing) estrogen levels in pregnancy. 22 Health care professionals may, therefore, find themselves caring for pregnant women with migraine. Preventive regimens during pregnancy are best managed in collaboration with a gynecologist and headache specialist.
Before the recent US Food and Drug Administration changes in pregnancy and lactation labeling, which went into effect in June 2015, sumatriptan was classified as a category C medication in pregnancy (ie, medications for which risk cannot be ruled out given a lack of adequate, well-controlled human studies; a chance of causing fetal harm exists, although the potential benefits may outweigh the risks) because offspring were harmed when extreme doses were given to pregnant rats. But researchers also calculated the highest no-effect (ie, safe) dose, which was 60 mg/kg daily, or the equivalent of 4200 mg/daily for a 70-kg person (the highest available dose is 100 mg). 24 An opinion stated in a 1998 literature review 25 opposed the use of triptans during pregnancy; however, a more recent review 26 did not find evidence of sumatriptan teratogenicity. These data included a prospective pregnancy registry from the United States and Canada. 26 In the large Norwegian Mother and Child Cohort Study, 27 2.2% of the 69,929 pregnant women in the study used a triptan during pregnancy (mostly sumatriptan). Triptan use during pregnancy was not associated with congenital malformations compared with controls. Adjusted odds ratios were 0.9 (95% CI, 0.7-1.2) for any malformation and 1.0 (95% CI, 0.7-1.3) for major congenital malformation. Similarly in Sweden, where more than 95% of all first-trimester drug exposures are identified through interviews with a midwife, the risk of birth defects (major or minor) was 3.6% in the general population. 28 With sumatriptan exposure in the first trimester (n¼2229), the risk was identical (3.6%).
Not all triptans should be considered safe during pregnancy. The relative hydrophilicity of sumatriptan makes it less likely to traverse the placental membrane (only about 15% of a sumatriptan dose crosses into the fetal compartment over 4 hours), whereas the other triptans are lipophilic.
The ideal choice for a triptan during pregnancy is sumatriptan administered either by the nasal delivery system or by nasal spray for 2 reasons: (1) they deliver maternal serum concentrations that are equivalent to or less than the 25-mg sumatriptan tablet 24 and (2) parenteral administration maintains efficacy in the presence of gastric stasis or nausea, which are conditions commonly present when migraines tend to peak at the end of the first trimester. To prevent medication overuse headache, triptans are usually limited to 9 days per month.
MIGRAINE TREATMENT DURING LACTATION
Nearly all maternal drugs that are compatible with breastfeeding will appear in the breast milk. Drugs that are relatively toxic are contraindicated during breastfeeding, but if the relative infant dose is no more than 10% of the mother's (an arbitrary cutoff), the drug is considered safe during lactation. 29 Both sumatriptan and eletriptan have low relative infant doses (0.2%-3.5%), suggesting that their use during lactation should not pose substantial risk to the infant. 30 The Canadian Headache Society 31 and the American Academy of Pediatrics 32 suggest that sumatriptan is compatible with lactation. In contrast, rizatriptan is concentrated in rat breast milk, with a relative infant dose at least 5 times greater than maternal plasma concentrations per product labeling. Current information on the excretion of drugs in breast milk and possible adverse effects in a nursing infant can be obtained on the new LactMed website. 33 Migraine prevention in lactation should center around good, restorative sleepdwhich can be difficult with a new baby. A good review of medication options for treatment during lactation can be found in an article commissioned by the American Headache Society. 34 As during pregnancy, sumatriptan at the lowest effective dose is the triptan of choice for lactating women.
MIGRAINE IN MENOPAUSE
Data are fairly consistent in showing a perimenopausal increase in migraine prevalence and a postmenopausal decrease. Additionally, the prevalence of high-frequency headache (ie, occurring 10 d/mo) is higher during perimenopause than during premenopausal years. 35 Sleep disturbances are common in women around the menopausal transition and likely contribute to this increased frequency.
Treatment strategies for perimenopausal migraineurs include minimizing decreases in estrogen levels, which may benefit not only migraine but also vasomotor symptoms. 36 Continuous or extended-cycle CHC can be used in perimenopause with consideration of estrogen add-back during the hormone-free interval to prevent estradiol levels from decreasing and triggering migraine ( Table 2) . Most women will see improvement in their migraines once in menopause. Menopausal hormone therapy can be used with certain caveats and is not contraindicated in postmenopausal women with migraine (with or without aura). 36 Fortunately, there is now clarity regarding the favorable risk-to-benefit balance for the use of menopausal hormone therapy in symptomatic women without contraindication who are in their 50s and within 10 years of the menopause transition. 37 For women with a history of MRM, administration should be transdermal in the lowest dose sufficient to meet treatment goals. 36 Oral estrogens with short half-lives and hormonal therapy injections should be avoided because both can produce problematic decreases in estrogen concentration between doses.
Triptans are commonly used as abortive therapy for migraine, and age alone is not a contraindication for their use. Women at low risk for cardiovascular disease can use triptans without additional cardiac assessment, but the use of triptans should be avoided in women (or men) with known coronary heart disease, uncontrolled hypertension, cerebrovascular syndromes (stroke or transient ischemic attack), or peripheral vascular disease (including ischemic bowel disease). 38 
CONCLUSION
Migraine is more prevalent in women than in men, and hormonal influences during the reproductive life cycle (including menarche, the use of CHC, pregnancy and lactation, and the menopause transition) affect not only the frequency and severity of migraine but also its treatment. Hormonal manipulation strategies aimed at eliminating or minimizing decreases in estrogen levels may prevent migraine attacks. The use of triptans may need to be modified in pregnant or lactating women and avoided in women with coronary heart disease or an equivalent disease. Health care professionals caring for women throughout their life should be familiar with these sex-based differences in women with migraine and with targeted strategies for management.
